Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Correspondence:
View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sibon, I.
Right arrow Articles by Orgogozo, J.-M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sibon, I.
Right arrow Articles by Orgogozo, J.-M.
Related Collections
Right arrow All Cerebrovascular disease/Stroke
Right arrow Risk factors in epidemiology
Right arrow Infarction
NEUROLOGY 2004;62:1187-1189
© 2004 American Academy of Neurology
Brief Communications

Antiplatelet drug discontinuation is a risk factor for ischemic stroke

Igor Sibon, MD and Jean-Marc Orgogozo, MD

From the Fédération de neurosciences cliniques, CHU Bordeaux, France.

Address correspondence and reprint requests to Dr. I. Sibon, Service de neurologie, CHU Pellegrin, Place Amélie Raba-Léon, 33076 Bordeaux cedex, France; e-mail: igor.sibon{at}chu-bordeaux.fr

Antiplatelet drugs (APD) are widely used in the prevention of ischemic cardio- and cerebrovascular diseases. The authors studied the frequency of stroke occurring after APD discontinuation, the cause of discontinuation, and the delay between APD disruption and stroke. Only 4.49% of strokes were related to a recent APD discontinuation, but all cases occurred between 6 and 10 days after drug discontinuation (p < 0.0001). This temporal pattern has biologic plausibility because the inhibited platelets circulate in the blood for about 10 days.

Received August 25, 2003. Accepted in final form November 26, 2003.




This article has been cited by other articles:


Home page
 Am. J. Roentgenol.Home page
S. D. O'Connor, A. J. Taylor, E. C. Williams, and T. C. Winter
Coagulation Concepts Update
Am. J. Roentgenol., December 1, 2009; 193(6): 1656 - 1664.
[Abstract] [Full Text] [PDF]

Home page
 CLIN APPL THROMB HEMOSTHome page
O. Aguejouf, F. Eizayaga, V. Desplat, P. Belon, and C. Doutremepuich
Prothrombotic and Hemorrhagic Effects of Aspirin
Clinical and Applied Thrombosis/Hemostasis, October 1, 2009; 15(5): 523 - 528.
[Abstract] [PDF]

Home page
 Eur Heart J SupplHome page
M. E. Bertrand
When and how to discontinue antiplatelet therapy
Eur. Heart J. Suppl., January 1, 2008; 10(suppl_A): A35 - A41.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
A. B. Maulaz, D. C. Bezerra, P. Michel, and J. Bogousslavsky
Effect of Discontinuing Aspirin Therapy on the Risk of Brain Ischemic Stroke
Arch Neurol, August 1, 2005; 62(8): 1217 - 1220.
[Abstract] [Full Text] [PDF]

Home page
 JWatch NeurologyHome page
Antiplatelet Drug Discontinuation May Increase Stroke Risk
Journal Watch Neurology, August 26, 2004; 2004(826): 1 - 1.
[Full Text]

Correspondence:

Read all Correspondence

Antiplatelet drug discontinuation is a risk factor for ischemic stroke
David S. Bachman MD, et al.
Neurology Online, 8 Jun 2004 [Full text]
Reply to Bachman
I. Sibon
Neurology Online, 8 Jun 2004 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.